# Safety, Tolerability, and Immunogenicity of Vaxelis™ in Children Previously Vaccinated With Vaxelis™ or Hexyon™ (V419-016)

> **NCT05289271** · PHASE4 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 168 (actual)

## Conditions studied

- Vaccines, Combined
- Hexavalent Vaccine

## Interventions

- **BIOLOGICAL:** Vaxelis™

## Key facts

- **NCT ID:** NCT05289271
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-25
- **Primary completion:** 2022-08-30
- **Final completion:** 2022-08-30
- **Target enrollment:** 168 (ACTUAL)
- **Last updated:** 2024-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05289271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05289271, "Safety, Tolerability, and Immunogenicity of Vaxelis™ in Children Previously Vaccinated With Vaxelis™ or Hexyon™ (V419-016)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05289271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*